Xeris Pharmaceuticals Inc. (XERS) Tops Q1 EPS by 3c; Offer Guidance

Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q1 EPS of ($0.12), $0.03 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $33.2 million versus the consensus estimate of $30.96 million.

GUIDANCE:

Xeris Pharmaceuticals Inc. sees FY2023 revenue of $135-165 million, versus the consensus of $146.9 million.

For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.

You May Also Be Interested In

• BofA raises AMD target to $720, sees server CPU TAM tripling to $211B by 2030
• Cracker Barrel (CBRL) Tops Q4 EPS by 89c, Offers Guidance
• Cintas Corp. (CTAS) Tops Q1 EPS by 1c, Offers Guidance